IgG antiphospholipid antibodies (aPL) against β2-glycoprotein I (β2GPI) can target any of its five domains; however, aPL against the N-terminal domain (anti-DI, aDI) are considered the most clinically relevant in the antiphospholipid syndrome (APS). Circulating levels of aDI are elevated in patients with APS compared with disease and healthy controls, and crucially aDI are prothrombotic in in vivo and in vitro models. In addition, human recombinant DI has been shown to abrogate aPL-induced thrombosis in vivo. Therefore, although the potential of utilizing DI for management of APS is not yet fully defined, there is promise that DI could prove valuable both as a diagnostic and therapeutic tool.
Ioannou Y, Zhang JY, Qi M, et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen beta2-glycoprotein I. Arthritis Rheum 2011; 63: 2774–2782.
2.
IversonGMVictoriaEJMarquisDM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A1998; 95: 15542–15546.
3.
McNeeleyPADlottJSFurieRA. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost2001; 86: 590–595.
4.
IversonGMReddelSVictoriaEJ. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol2002; 169: 7097–7103.
5.
IoannouYPericleousCGilesILatchmanDSIsenbergDARahmanA. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum2007; 56: 280–290.
6.
de LaatBDerksenRHvan LummelMPenningsMTde GrootPG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood2006; 107: 1916–1924.
7.
AgarCvan OsGMMorgelinM. Beta2-glycoprotein I can exist in 2 conformations: Implications for our understanding of the antiphospholipid syndrome. Blood2010; 116: 1336–1343.
8.
de LaatBDerksenRHUrbanusRTde GrootPG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood2005; 105: 1540–1545.
9.
de LaatBPengoVPabingerI. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: An international multicenter study. J Thromb Haemost2009; 7: 1767–1773.
10.
AndreoliLNalliCMottaM. Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: Might it be the reason for their ‘innocent' profile?Ann Rheum Dis2011; 70: 380–383.
11.
de LaatBWuXXvan LummelMDerksenRHde GrootPGRandJH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood2007; 109: 1490–1494.
12.
WaheziDMIlowiteNTWuXX. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of beta2-glycoprotein I. Lupus2013; 22: 702–711.
13.
PericleousCRuiz-LimonPRomay-PenabadZ. Affinitty-purified antibodies directed to domain I of beta 2GPI are pathogenic in a mouse model of thrombosis. Arthritis Rheum2012; 64: S740–S740.
14.
PericleousCMilesJEspositoD. Evaluating the conformation of recombinant domain I of beta(2)-glycoprotein I and its interaction with human monoclonal antibodies. Mol Immunol2011; 49: 56–63.
15.
PierangeliSSLiuXEspinolaR. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost2000; 84: 388–395.
16.
GilesIPericleousCLiuX. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol2009; 182: 4836–4843.
17.
IoannouYRomay-PenabadZPericleousC. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: Proof of concept. J Thromb Haemost2009; 7: 833–842.
18.
AgostinisCDuriguttoPSblatteroD. A non complement-fixing antibody to beta2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood2014; 123: 3478–3487.
19.
ColasantiTAlessandriCCapozziA. Autoantibodies specific to a peptide of beta2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood2012; 120: 3360–3370.
20.
de LaatBvan BerkelMUrbanusRT. Immune responses against domain I of beta(2)-glycoprotein I are driven by conformational changes: Domain I of beta(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum2011; 63: 3960–3968.
21.
PierangeliSSde GrootPGDlottJ. Criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus2011; 20: 182–190.
22.
BertolacciniMLAmengualOAtsumiT. Non-criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus2011; 20: 191–205.
23.
Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; doi: 10.1016/j.autrev.2014.05.001. [Epub ahead of print].
24.
IoannouYGilesILambrianidesA. A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. BMC Biotechnol2006; 6: 8–8.
25.
BanzatoAPozziNFrassonR. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res2011; 128: 583–586.
26.
AkhterEShumsZNormanGLBinderWFangHPetriM. Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol2013; 40: 282–286.
27.
MahlerMNormanGLMeroniPLKhamashtaM. Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev2012; 12: 313–317.
28.
MondejarRGonzalez-RodriguezCToyos-Saenz de MieraFJ. Role of antiphospholipid score and anti-beta2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta2014; 431C: 174–178.
